Bristol Myers Squibb Company $BMY Shares Sold by Curi RMB Capital LLC

Key Points

• Curi RMB Capital LLC significantly reduced its stake in Bristol Myers Squibb by 76.3%, ending with 4,869 shares valued at approximately $297,000.
• Insider transactions include EVP David V. Elkins selling 56,000 shares for over $2.65 million, resulting in a 25.07% decrease in his ownership.
• Bristol Myers Squibb's recent earnings report showed an EPS of $1.46, surpassing estimates, and the company has set its FY 2025 guidance at 6.350-6.650 EPS.

Curi RMB Capital LLC cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 76.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,869 shares of the biopharmaceutical company's stock after selling 15,666 shares during the quarter. Curi RMB Capital LLC's holdings in Bristol Myers Squibb were worth $297,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Wellington Management Group LLP grew its holdings in shares of Bristol Myers Squibb by 297.0% during the first quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock worth $1,447,198,000 after buying an additional 17,750,938 shares in the last quarter. GQG Partners LLC grew its holdings in shares of Bristol Myers Squibb by 22,647.6% during the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock worth $733,310,000 after buying an additional 11,970,598 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Bristol Myers Squibb during the first quarter worth about $624,369,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Bristol Myers Squibb by 16.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,271,742 shares of the biopharmaceutical company's stock worth $1,259,690,000 after buying an additional 3,196,919 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Bristol Myers Squibb by 7,142.8% during the first quarter. GAMMA Investing LLC now owns 2,420,388 shares of the biopharmaceutical company's stock worth $147,619,000 after buying an additional 2,386,970 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Trading Up 0.9%

BMY stock traded up $0.43 during midday trading on Thursday, reaching $47.58. 4,931,710 shares of the company's stock traded hands, compared to its average volume of 12,947,549. The company has a market capitalization of $96.85 billion, a P/E ratio of 19.19, a PEG ratio of 2.42 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The business has a 50-day moving average price of $47.08 and a two-hundred day moving average price of $50.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb's revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Citigroup decreased their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Finally, Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.